Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.

Abstract excerpt

Imatinib mesylate, binding to the inactive conformation of Bcr-Abl tyrosine kinase and suppressing the Ph chromosome positive clone, has revolutionized the treatment of chronic myeloid leukaemia (CML) patients. Given the high rates of clinical and cytogenetic remission achieved, the molecular mon...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Fusion Proteins, bcr-abl
• Share to Gene Expression Regulation, Leukemic